Jazz Pharmaceuticals to pay $20 million in penalties and compensation

Share this article:
Jazz Pharmaceuticals will pay $20 million in penalties and victim compensation to resolve criminal and civil investigations into illegal marketing by its Orphan Medical wholly owned subsidiary. The US Attorney for New York's Eastern District says Orphan pled guilty to felony misbranding for illegal promotion of Xyrem for unapproved uses.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Legal/Regulatory

This compelling e-book shares a wealth of insights designed to help members of sales forces connect with elusive HCPs. An expanded version has also been created that includes video interviews and other multimedia content. Click here for access.